Advertisement
YOU ARE HERE: LAT HomeCollectionsLyphomed Inc
IN THE NEWS

Lyphomed Inc

FEATURED ARTICLES
ARTICLES BY DATE
NEWS
October 12, 1989 | From Associated Press
Lyphomed Inc. has been distributing its drug pentamidine, used to combat AIDS-linked pneumonia, free to poor patients, the company said Wednesday. The company announced its plans to give away the drug in February, but the actual distribution was held up until after the drug won full government approval in June, said spokeswoman Melissa Marsden. Community health organizations were notified of the availability of pentamidine for the poor and for those who lacked insurance to cover its costs.
Advertisement
NEWS
October 12, 1989 | From Associated Press
Lyphomed Inc. has been distributing its drug pentamidine, used to combat AIDS-linked pneumonia, free to poor patients, the company said Wednesday. The company announced its plans to give away the drug in February, but the actual distribution was held up until after the drug won full government approval in June, said spokeswoman Melissa Marsden. Community health organizations were notified of the availability of pentamidine for the poor and for those who lacked insurance to cover its costs.
BUSINESS
August 22, 1989 | From Associated Press
A large Japanese pharmaceutical maker that already owns 30% of Lyphomed Inc.'s stock has offered $649 million for the rest of the drug company, Lyphomed announced Monday. John N. Kapoor, Lyphomed's chairman and founder, already has agreed to sell his 14% stake in the company to suitor Fujisawa Pharmaceuticals Co. if the Lyphomed board approves the deal, a company statement read.
NEWS
December 1, 1988 | ROBERT STEINBROOK, Times Medical Writer
In an article likely to spark controversy, researchers at the prestigious Memorial Sloan-Kettering Cancer Center in New York City have called for curtailed use of aerosol pentamidine, a widespread experimental therapy for a pneumonia that afflicts AIDS patients. "Aerosol pentamidine should not be used for treatment of pneumocystis pneumonia and should be used as (a preventive measure) only in careful clinical trials," Dr.
NEWS
February 1, 1989 | ROBERT STEINBROOK, Times Medical Writer
The U.S Food and Drug Administration will approve widespread distribution of an experimental drug that has been shown to prevent pneumocystis carinii pneumonia, the most common life-threatening infection seen in AIDS patients, agency officials said Tuesday.
BUSINESS
August 7, 1985 | DJ
Dexter Corp. said its 64%-owned subsidiary, Life Technologies Inc., sold its Invenex Laboratories division to Lyphomed Inc. of Chicago.
BUSINESS
September 1, 1989 | From Times wire services
Lyphomed Inc. said today it has agreed to be bought by Fujisawa Pharmaceutical Co. Ltd., a Japanese firm that already owns 30% of the drug manufacturer, for about $670 million. Lyphomed, based in the Chicago suburb of Rosemont, enjoyed explosive growth in the mid-1980s, largely through its sales of pentamidine, a drug used to treat AIDS-related pneumonia. Overall sales soared from $4 million to $172 million from 1981 through 1987.
NEWS
May 2, 1989 | From Times Wire Services
Final marketing approval for aerosol Pentamidine, a drug to prevent AIDS-related pneumonia, was unanimously recommended Monday by a Food and Drug Administration advisory committee. FDA officials said the drug, made by Lyphomed Inc. of Melrose Park, Ill., could gain final agency approval "in a matter of weeks." The drug is already widely available to AIDS patients in this country under a special FDA effort to cut through red tape when desperately ill or dying patients are involved.
BUSINESS
August 22, 1989 | From Associated Press
A large Japanese pharmaceutical maker that already owns 30% of Lyphomed Inc.'s stock has offered $649 million for the rest of the drug company, Lyphomed announced Monday. John N. Kapoor, Lyphomed's chairman and founder, already has agreed to sell his 14% stake in the company to suitor Fujisawa Pharmaceuticals Co. if the Lyphomed board approves the deal, a company statement read.
NEWS
February 1, 1989 | ROBERT STEINBROOK, Times Medical Writer
The U.S Food and Drug Administration will approve widespread distribution of an experimental drug that has been shown to prevent pneumocystis carinii pneumonia, the most common life-threatening infection seen in AIDS patients, agency officials said Tuesday.
NEWS
December 1, 1988 | ROBERT STEINBROOK, Times Medical Writer
In an article likely to spark controversy, researchers at the prestigious Memorial Sloan-Kettering Cancer Center in New York City have called for curtailed use of aerosol pentamidine, a widespread experimental therapy for a pneumonia that afflicts AIDS patients. "Aerosol pentamidine should not be used for treatment of pneumocystis pneumonia and should be used as (a preventive measure) only in careful clinical trials," Dr.
NEWS
November 5, 1988 | Associated Press
The Food and Drug Administration warned physicians Friday that three patients receiving intravenous feedings have died recently due to a lack of Vitamin B1, and the agency urged doctors to make sure such liquid diets are supplemented with the essential vitamin. A multivitamin preparation usually added to intravenous feedings is in short supply because a Chicago manufacturer, Lyphomed Inc., had to cut production after the FDA ordered a recall in July of some of the company's product.
NEWS
June 16, 1989 | ROBERT STEINBROOK, Times Medical Writer
The U.S. Food and Drug Administration on Thursday approved prescription sales of aerosol pentamidine, a medication to prevent Pneumocystis carinii pneumonia, the most common life-threatening infection seen in AIDS patients. The medication is already widely used by AIDS patients under a expanded distribution scheme announced by the FDA in February, and final marketing approval had been expected. But the federal action ensures that almost all health insurers will now cover the expensive monthly treatments.
Los Angeles Times Articles
|